This firm currently holds 646.93
M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating Clovis Oncology may have difficulties to generate enough cash to satisfy its financial obligations. The company has a current ratio of 1.65, which is within standard range for the sector.
On a scale of 0 to 100, Clovis Oncology holds a
performance score of 8. The firm shows a Beta (market volatility) of 0.3783, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Clovis's beta means in this case. As returns on the market increase, Clovis Oncology returns are expected to increase less than the market. However, during the bear market, the loss on holding Clovis Oncology will be expected to be smaller as well. Although it is vital to follow
Clovis Oncology historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing
future performance of any stock is to evaluate the business as a whole together with its past performance, including all
available fundamental and
technical indicators. We have found twenty-seven
technical indicators for Clovis Oncology, which you can use to evaluate the performance of the firm. Please makes use of Clovis Oncology
maximum drawdown, as well as the
relationship between the skewness and
day typical price to make a quick decision on whether Clovis Oncology
price patterns will revert.
Volatility is a rate at which the price of Clovis Oncology or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Clovis Oncology may increase or decrease. In other words, similar to Clovis's
beta indicator, it measures the risk of Clovis Oncology and helps estimate the fluctuations that may happen in a short period of time. So if prices of Clovis Oncology fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our
technical analysis page.
Watch out for price decline
Please consider monitoring Clovis Oncology on a daily basis if you are holding a position in it. Clovis Oncology is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Clovis Oncology stock to be traded above the $1 level to remain listed. If Clovis Oncology stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Clovis Oncology's Liquidity
Clovis Oncology
financial leverage refers to using borrowed capital as a funding source to finance Clovis Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Clovis Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Clovis Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Clovis Oncology's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Clovis Oncology's total debt and its cash.
Another angle On Clovis Oncology
The latest price spike of Clovis Oncology could raise concerns from retail investors as the firm it trading at a share price of
7.86 on
331,266,000 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
April. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.69. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Clovis Oncology partners.
Another 3 percent spike for Clovis Oncology
Latest coefficient of variation is at 942.07.
As of the 20th of March, Clovis Oncology shows the Risk Adjusted Performance of 0.0968,
downside deviation of 5.01, and Mean Deviation of 5.65. Clovis Oncology
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Clovis Oncology, which can be compared to its rivals. Please confirm
Clovis Oncology coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to decide if Clovis Oncology is priced correctly, providing market reflects its regular price of 7.86 per share. Given that Clovis Oncology has
jensen alpha of 0.8445, we suggest you to validate Clovis Oncology's prevailing market performance to make sure the company can sustain itself at a future point.
Our Final Take On Clovis Oncology
While few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Clovis Oncology may offer a potential longer-term growth to retail investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither trade nor sell any shares of Clovis Oncology at this time. The Clovis Oncology risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Clovis Oncology.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Clovis Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com